Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Bristol-Myers Squibb Company (NYSE: BMY) announced the accepted amounts and pricing terms of its tender offers to purchase for cash its outstanding notes. The company decreased the maximum aggregate purchase price of Pool 1 Notes and increased the maximum aggregate purchase price of Pool 2 Notes.
The tables below outline the aggregate principal amount of Notes tendered and accepted, the Offer Yield, the proration factor, and the total consideration for each $1,000 principal amount of each series of Notes validly tendered at or before the Early Tender Deadline.
Pool 1 Notes and Pool 2 Notes are referred to collectively as the 'Notes', with each series of Notes called a 'series'. The offers to purchase each series of Notes for cash are called 'Offers', with the Pool 1 Offers and Pool 2 Offers collectively referred to as 'Pool Offers'.
The withdrawal rights for the Offers expired on November 17, 2025, and all conditions were met by the Early Tender Deadline. Bristol Myers Squibb has elected to exercise its Early Settlement Right, with the Early Settlement Date set for November 20, 2025. The Offers will expire on December 3, 2025, unless extended or terminated earlier.
The Total Consideration does not include accrued and unpaid interest on the Notes up to the Early Settlement Date. All accepted Notes will be cancelled and retired, no longer remaining outstanding obligations of Bristol Myers Squibb. Questions regarding the terms and conditions of the Offers can be directed to the designated financial institutions.
